Biotage signs agreement to acquire UK’s ATDBio
Merging ATDBio’s oligonucleotide production skills with the one-stop-shop customer workflow of Biotage offers high potential.
Deals
Amgen concludes acquisition of biotech company Teneobio for $2.5bn
Teneobio’s three affiliates, TeneoTwo, TeneoFour and TeneoTen, were spun off to its present equity holders.
Silence and Hansoh partner to develop siRNA-based treatments
Silence is eligible to receive potential milestone payments of up to $1.3bn and royalties on...
Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio
The transaction advances studies of FX201 and FX301 for the treatment of musculoskeletal pain and...
Supernus Pharmaceuticals signs agreement to acquire Adamas for $450m
Supernus will get access to Adamas’ two commercial products, Gocovri and Osmolex ER.
Sandoz acquires cephalosporin antibiotics business of GSK
Through the acquisition of GSK's cephalosporin antibiotics business, Sandoz obtained the rights to GSK’s Zinnat, Zinacef and Fortum brands.
Takeda and JCR Pharmaceuticals partner to market Hunter syndrome therapy
Takeda will gain an exclusive right to market JR-141 outside of the US, excluding Japan and some other Asia-Pacific nations.
Merck agrees to acquire Acceleron Pharma for $11.5bn
Merck will gain rights to Acceleron’s lead therapy candidate, sotatercept, intended to treat pulmonary arterial hypertension.
AstraZeneca’s Alexion to acquire Caelum Biosciences for $500m
Alexion will gain rights to Caelum’s fibril-reactive monoclonal antibody CAEL-101 intended for the treatment of AL amyloidosis.
Union therapeutics signs deal with Innovent to develop orismilast in China
According to the agreement, Union therapeutics will retain international rights to orismilast outside of China.
Syndax collaborates with Incyte to develop monoclonal antibody
The antibody will be developed to treat chronic graft-versus-host disease and other immune-mediated diseases.
